Everyday Beauty Products Can Cause Serious Eye Injuries
Applying mascara, using eyelash glue or reaching for a heated curling tool may seem like harmless parts of a daily beauty routine. However, these familiar products can cause serious eye injuries when chemicals, hot surfaces or small objects come into contact with the eye.
New findings presented at the 130th annual meeting of the American Academy of Ophthalmology (AAO) highlight the risks associated with cosmetic and personal care products. The research also examines how injuries differ between children and adults, providing useful information for preventing avoidable eye damage.
The findings are part of three important developments in ophthalmology: cosmetic-related eye injuries, a retinal implant designed to restore some lost vision, and an artificial lens that delivers glaucoma medication after cataract surgery.
Cosmetic Products Account for Thousands of Eye Injuries
A study examining two decades of emergency department records identified 42,457 cosmetic-related eye injuries in the United States between 2005 and 2024. That represents approximately 2,100 emergency visits annually, equivalent to nearly six cases every day.
The research team used the National Electronic Injury Surveillance System (NEISS), a federal database that collects information from emergency departments and estimates injury patterns across the country.
According to the American Academy of Ophthalmology’s October 8, 2026, announcement, women and girls accounted for 81.8% of the reported injuries. The average age of affected individuals was 24, while children aged four and younger represented nearly one-quarter of all cases.
Most incidents occurred inside the home, accounting for 63% of injuries. Thermal burns represented approximately 26% of cases, while chemical exposures accounted for approximately 25%.
These findings demonstrate that everyday grooming activities can expose people to different types of eye hazards, depending on their age and the products involved.
Children and Adults Face Different Risks
The study identified noticeable differences between childhood and adult injuries. Among younger patients, chemical burns represented 45.8% of injuries, compared with just 0.5% among adults.
Researchers also found that 83.2% of all chemical burns were associated with children gaining access to cosmetic products. Among children aged four and younger, 70% were injured after reaching for a product without supervision.
Adult injuries followed a different pattern. Approximately 90% of injured adults were applying the cosmetic or personal care product themselves rather than receiving assistance from a professional.
These differences suggest that prevention strategies should consider the circumstances surrounding each age group. Keeping cosmetics, sprays and beauty liquids away from young children is particularly important, while adults should pay attention to heated styling equipment and grooming instruments.
How to Protect Your Eyes During Beauty Routines
Simple precautions can reduce the likelihood of cosmetic-related eye injuries. Parents should store beauty products in secure locations, especially items containing liquids, adhesives and chemical ingredients.
Adults should inspect heated eyelash curlers, hair styling tools and other grooming equipment before use. Avoid placing hot instruments too close to the eyes, and follow the manufacturer’s safety instructions.
Cosmetic products should also be used according to their intended purpose. Products that cause irritation should not be allowed to remain in contact with the eyes.
Retinal Implant Offers Hope for People With Advanced Macular Degeneration
Another development highlighted in the ophthalmology news concerns geographic atrophy, an advanced form of age-related macular degeneration (AMD).
This condition damages the macula, the central part of the retina responsible for detailed vision. As retinal cells deteriorate, patients can experience increasing difficulty reading, recognizing faces and performing activities that require clear central vision.
Existing medications can slow the progression of geographic atrophy in certain patients, but they cannot restore retinal cells that have already been lost. Researchers are therefore investigating technologies that may help recover some visual function.
One promising approach is the PRIMA retinal implant, a wireless electronic device developed by Science Corporation, a California-based company.
How the PRIMA System Works
The PRIMA system combines a small implant placed underneath the retina with specialized glasses containing a camera. The implant measures approximately two millimeters across and is thinner than a human hair.
After the implant is surgically positioned beneath the damaged retinal area, the patient wears glasses that capture images of the surrounding environment. The glasses then project the visual information onto the implant using infrared light.
The chip converts these signals into electrical stimulation, which travels through surviving retinal cells and ultimately reaches the brain. The technology is designed to provide visual information in areas where the natural light-sensing cells have stopped functioning.
The system is particularly relevant to people with advanced geographic atrophy who have already experienced substantial central vision loss.
Three-Year Results From the PRIMAvera Trial
New findings from the PRIMAvera clinical trial were presented at the 130th annual meeting of the American Academy of Ophthalmology in October 2026.
The European study enrolled 38 patients across 17 medical centers. Participants underwent implantation surgery and subsequently completed vision rehabilitation to learn how to use the technology.
At the 36-month assessment, 27 of the original 38 participants were available for safety evaluation, while 18 were assessed for treatment effectiveness. The reported findings suggested that vision improvements achieved with the implant could be maintained over three years.
However, the results require careful interpretation. The trial did not include a control group, and the available information did not explain why some original participants were not evaluated at the final assessment.
Most serious complications occurred during the first year and were associated with the implantation procedure. Between months 13 and 36, three patients each experienced one serious eye-related adverse event.
The findings were also reported by the American Academy of Ophthalmology with reference to the New England Journal of Medicine. PRIMA received the CE mark in July 2026, allowing it to be marketed in Europe, but it had not received approval in the United States at the time of the announcement.
New Artificial Lens Combines Cataract Surgery and Glaucoma Treatment
Glaucoma management often requires patients to use medicated eye drops consistently to control intraocular pressure. However, maintaining a daily treatment routine can be difficult, particularly for older adults managing several medications.
Some patients struggle with administering drops correctly, remembering multiple applications or managing treatment costs and side effects.
A new investigational artificial lens could offer another approach for certain patients who need cataract surgery and also have glaucoma or ocular hypertension.
How the Drug-Releasing Lens Works
The technology incorporates small medication-releasing pads into an artificial intraocular lens. During cataract surgery, the surgeon replaces the patient’s cloudy natural lens with the specialized implant.
The implanted lens gradually releases bimatoprost, a medication commonly used to lower eye pressure in people with glaucoma. This approach aims to deliver medication inside the eye without requiring the same daily drop routine.
The American Academy of Ophthalmology reported the findings on October 10, 2026, following a presentation at its 130th annual meeting.
What the Clinical Trial Found
The Phase 1/2 clinical trial included 106 adults with glaucoma or ocular hypertension who were scheduled to undergo cataract surgery.
Participants were assigned to three treatment groups. Two groups received artificial lenses containing different amounts of bimatoprost, while the comparison group received a standard artificial lens and timolol eye drops.
After 12 months, the average intraocular pressure measurements had decreased to 15.9 mmHg in the higher-dose implant group, 14.8 mmHg in the lower-dose group and 15.7 mmHg in the standard-lens group receiving timolol.
The pressure reductions in the implant groups were statistically comparable to those achieved with conventional medication. Additionally, more than 95% of participants receiving the drug-releasing lens did not require glaucoma medication at the one-year assessment.
Every eye receiving the specialized implant achieved corrected vision of 20/32 or better after 12 months. Researchers also reported comparable safety across the three groups, with no serious adverse events reported during the study period.
Although these results are encouraging, the findings represent an interim assessment rather than definitive evidence of long-term effectiveness.
What Happens Next for These Eye Health Developments?
The three developments demonstrate different approaches to protecting and improving vision. Cosmetic injury research focuses on preventing avoidable damage, while retinal implants and drug-releasing lenses explore new possibilities for patients with existing eye conditions.
The PRIMAvera research will remain important as investigators evaluate long-term outcomes and the technology’s performance outside clinical trials. Its availability in Europe and the absence of US approval are also important considerations for patients interested in the procedure.
Meanwhile, the glaucoma lens requires additional evaluation. Participants in its Phase 1/2 trial will be followed for three years, and two larger Phase 3 trials are underway to investigate its effectiveness and safety further.
When Should You See an Eye Doctor?
People should not ignore eye discomfort following exposure to cosmetics, grooming equipment or other potentially harmful substances. Eye injuries can affect the cornea, conjunctiva and deeper structures, depending on the source and severity of exposure.
Seek urgent medical attention after a suspected chemical eye injury, thermal burn or sudden change in vision. Severe pain, persistent redness, light sensitivity, blurred vision, excessive tearing and difficulty opening the eye are symptoms that require prompt assessment.
Eye specialists may perform visual acuity testing, slit-lamp examination, fluorescein staining and intraocular pressure measurement when appropriate. These examinations help identify damage and determine whether additional treatment or monitoring is necessary.
For people living with glaucoma or age-related macular degeneration, regular ophthalmology appointments remain important even when symptoms appear stable. Early assessment and continued monitoring can help identify changes before they cause additional functional difficulties.
Practical Steps for Protecting Long-Term Vision
Families can start by reviewing how cosmetics and personal care products are stored at home. Adults should also use heated grooming equipment carefully and avoid exposing their eyes to unnecessary risks.
People diagnosed with glaucoma should continue following their prescribed treatment plan rather than stopping medication because of emerging research. Patients considering cataract surgery or newer retinal technologies should discuss their eligibility, potential benefits and limitations with a qualified ophthalmologist.
As additional clinical trial results become available, the next important developments to watch will be the longer-term safety of the PRIMA retinal implant, the progress of Phase 3 trials for the drug-releasing lens and further research into preventing cosmetic-related eye injuries.
For now, protecting vision starts with practical prevention, recognizing warning signs and scheduling regular eye examinations with an eye care professional.
